Abteilung für Hämatologie und Internistische Onkologie

Veröffentlichungen in 2015

  • White H, Deprez L, Corbisier P, Hall V, Lin F, Mazoua S, Trapmann S, Aggerholm A, Andrikovics H, Akiki S, Barbany G, Boeckx N, Bench A, Catherwood M, Cayuela JM, Chudleigh S, Clench T, Colomer D, Dara: A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCR. In: Leukemia 2015; 29(2): 369-376 [IF 10,431]
  • Niederwieser C, Kohlschmidt J, Volinia S, Whitman SP, Metzeler KH, Eisfeld AK, Maharry K, Yan P, Frankhouser D, Becker H, Schwind S, Carroll AJ, Nicolet D, Mendler JH, Curfman JP, Wu YZ, Baer MR, Powe: Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia. In: Leukemia 2015; 29(3): 567-575 [IF 10,431]
  • Cross NC, White HE, Colomer D, Ehrencrona H, Foroni L, Gottardi E, Lange T, Lion T, Machova Polakova K, Dulucq S, Martinelli G, Oppliger Leibundgut E, Pallisgaard N, Barbany G, Sacha T, Talmaci R, Izz: Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. In: Leukemia 2015; 29(5): 999-1003 [IF 10,431]
  • Wenn K, Tomala L, Wilop S, Vankann L, Hasenbank C, Frank O, Hochhaus A, Giles FJ, Lange T, Muller MC, Koschmieder S, Beier F, Ziegler P, Brummendorf TH: Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib. In: Leukemia 2015; 29(12): 2402-2404 [IF 10,431]
  • Kroger NM, Deeg JH, Olavarria E, Niederwieser D, Bacigalupo A, Barbui T, Rambaldi A, Mesa R, Tefferi A, Griesshammer M, Gupta V, Harrison C, Alchalby H, Vannucchi AM, Cervantes F, Robin M, Ditschkowsk: Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group. In: Leukemia 2015; 29(11): 2126-2133 [IF 10,431]
  • Versluis J, Labopin M, Niederwieser D, Socie G, Schlenk RF, Milpied N, Nagler A, Blaise D, Rocha V, Cornelissen JJ, Mohty M: Prediction of non-relapse mortality in recipients of reduced intensity conditioning allogeneic stem cell transplantation with AML in first complete remission. In: Leukemia 2015; 29(1): 51-57 [IF 10,431]
  • Schmidt C, Fingerle-Rowson G, Boehme A, Brendel K, Fischer R, Gonnermann M, Hohler T, Kegel T, Kellermann L, Nusch A, Ponisch W, Wendtner C, Dreyling M: Changes in the diagnosis and treatment of patients with low grade lymphoma in Germany: years 2006-2009. In: Leuk Lymphoma 2015; 56(3): 694-702 [IF 2,891]
  • Beyer S, Pfrepper C, Kronberg J, Vucinic V, Ziemer M, Simon JC, Niederwieser D, Treudler R: Severe cutaneous necroses and hemorrhagic diathesis in a 73-year-old man. In: J Dtsch Dermatol Ges 2015; 13(3): 252-255 [IF 2,05]
  • Lee AY, Kamphuisen PW, Meyer G, Bauersachs R, Janas MS, Jarner MF, Khorana AA: Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial. In: JAMA 2015; 314(7): 677-686 [IF 35,289]
  • Vannucchi AM, Kantarjian HM, Kiladjian JJ, Gotlib J, Cervantes F, Mesa RA, Sarlis NJ, Peng W, Sandor V, Gopalakrishna P, Hmissi A, Stalbovskaya V, Gupta V, Harrison C, Verstovsek S: A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. In: Haematologica 2015; 100(9): 1139-1145 [IF 5,814]
  • Ludwig H, Rauch E, Kuehr T, Adam Z, Weissmann A, Kasparu H, Autzinger EM, Heintel D, Greil R, Poenisch W, Muldur E, Zojer N: Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study. In: Haematologica 2015; 100(3): 385-391 [IF 5,814]
  • Vaughn JE, Sorror ML, Storer BE, Chauncey TR, Pulsipher MA, Maziarz RT, Maris MB, Hari P, Laport GG, Franke GN, Agura ED, Langston AA, Rezvani AR, Storb R, Sandmaier BM, Maloney DG: Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. In: Cancer 2015; 121(20): 3709-3716 [IF 5,068]
  • Iacobelli S, de Wreede LC, Schonland S, Bjorkstrand B, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Carella AM, Beksac M, Bosi A, Milone G, Corradini P, Friberg K, van Biezen A, Goldschmidt H, : Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial. In: Bone Marrow Transplant 2015; 50(4): 505-510 [IF 3,57]
  • Ruutu T, de Wreede LC, van Biezen A, Brand R, Mohty M, Dreger P, Duarte R, Peters C, Garderet L, Schonland S, Gratwohl A, Niederwieser D, de Witte T, Kroger N: Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT. In: Bone Marrow Transplant 2015; 50(12): 1542-1550 [IF 3,57]
  • Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH, Kumar R, Cavenagh J, Schuh AC, Candoni A, Recher C, Sandhu I, Bernal del Castillo T, Al-Ali HK, Martinelli G, Falantes J, Noppeney: International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. In: Blood 2015; 126(3): 291-299 [IF 10,452]
  • Radujkovic A, Guglielmi C, Bergantini S, Iacobelli S, van Biezen A, Milojkovic D, Gratwohl A, Schattenberg AV, Verdonck LF, Niederwieser DW, de Witte T, Kroger N, Olavarria E: Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease? In: Biol Blood Marrow Transplant 2015; 21(7): 1230-1236 [IF 3,404]
  • Robin M, Ruggeri A, Labopin M, Niederwieser D, Tabrizi R, Sanz G, Bourhis JH, van Biezen A, Koenecke C, Blaise D, Tischer J, Craddock C, Maillard N, Mohty M, Russel N, Schetelig J, Finke J, Gluckman E: Comparison of Unrelated Cord Blood and Peripheral Blood Stem Cell Transplantation in Adults with Myelodysplastic Syndrome after Reduced-Intensity Conditioning Regimen: A Collaborative Study from Eurocord (Cord blood Committee of Cellular Therapy & Immunobiology Working Party of EBMT) and Chronic Malignancies Working Party. In: Biol Blood Marrow Transplant 2015; 21(3): 489-495 [IF 3,404]
  • Worel N, Buser A, Greinix HT, Hagglund H, Navarro W, Pulsipher MA, Nicoloso de Faveri G, Bengtsson M, Billen A, Espino G, Fechter M, Giudice V, Holig K, Kanamori H, Kodera Y, Leitner G, Netelenbos T, : Suitability Criteria for Adult Related Donors: A Consensus Statement from the Worldwide Network for Blood and Marrow Transplantation Standing Committee on Donor Issues. In: Biol Blood Marrow Transplant 2015; 21(12): 2052-2060 [IF 3,404]
  • Thiel A, Schetelig J, Ponisch W, Schafer-Eckart K, Aulitzky W, Peter N, Schulze A, Maschmeyer G, Neugebauer S, Herbst R, Hanel A, Morgner A, Kroschinsky F, Bornhauser M, Lange T, Wilhelm M, Niederwies: Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML--long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL). In: Ann Oncol 2015; 26(7): 1434-1440 [IF 7,04]
  • Gerloff D, Grundler R, Wurm AA, Brauer-Hartmann D, Katzerke C, Hartmann JU, Madan V, Muller-Tidow C, Duyster J, Tenen DG, Niederwieser D, Behre G: NF-kB/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia. In: Leukemia 2015; 29(3): 535-547 [IF 10,431]
  • Gratwohl A, Pasquini MC, Aljurf M, Atsuta Y, Baldomero H, Foeken L, Gratwohl M, Bouzas LF, Confer D, Frauendorfer K, Gluckman E, Greinix H, Horowitz M, Iida M, Lipton J, Madrigal A, Mohty M, Noel L, Novitzky N, Nunez J, Oudshoorn M, Passweg J, van Rood J, Szer J, Blume K, Appelbaum FR, Kodera Y, Niederwieser D: One million haemopoietic stem-cell transplants: a retrospective observational study. In: Lancet Haematol 2015; 2(3): e91-e100 [IF 0]
  • Maschmeyer G, Mugge LO, Kampfe D, Kreibich U, Wilhelm S, Assmann M, Schwarz M, Kahl C, Kohler S, Grobe N, Niederwieser D: A retrospective review of diagnosis and treatment modalities of neuroendocrine tumors (excluding primary lung cancer) in 10 oncological institutions of the East German Study Group of Hematology and Oncology (OSHO), 2010-2012. In: J Cancer Res Clin Oncol 2015; 141(9): 1639-1644 [IF 3,081]
  • Rockstroh A, Al-Ali HK, Lange T, Ponisch W, Krahl R, Cross M, Behre G, Niederwieser D, Pfrepper C: Comparable outcome after single-antigen-mismatched versus matched unrelated donor haematopoietic cell transplantation. In: J Cancer Res Clin Oncol 2015; 141(12): 2193-2203 [IF 3,081]
  • Poenisch W, Plotze M, Holzvogt B, Andrea M, Schliwa T, Zehrfeld T, Hammerschmidt D, Schwarz M, Edelmann T, Becker C, Hoffmann FA, Schwarzer A, Kreibich U, Gutsche K, Reifenrath K, Schwarzbach H, Heyn S, Franke GN, Jentzsch M, Leiblein S, Schwind S, Lange T, Vucinic V, AlAli HK, Niederwieser D: Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma. In: J Cancer Res Clin Oncol 2015; 141(11): 2013-2022 [IF 3,081]
  • McMullin MF, Harrison CN, Niederwieser D, Demuynck H, Jakel N, Gopalakrishna P, McQuitty M, Stalbovskaya V, Recher C, Theunissen K, Gisslinger H, Kiladjian JJ, Al-Ali HK: The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis. In: Exp Hematol Oncol 2015; 4: 26 [IF 0]
  • Brauer-Hartmann D, Hartmann JU, Wurm AA, Gerloff D, Katzerke C, Verga Falzacappa MV, Pelicci PG, Muller-Tidow C, Tenen DG, Niederwieser D, Behre G: PML/RAR?-Regulated miR-181a/b Cluster Targets the Tumor Suppressor RASSF1A in Acute Promyelocytic Leukemia. In: Cancer Res 2015; 75(16): 3411-3424 [IF 9,329]
  • Koehler A, Hubert K, Lange T, Siebolts U, Wickenhauser C, Gopalakrishna P, Niederwieser D, Monecke A, Al-Ali HK: JAK2V617F molecular remission in a primary myelofibrosis patient treated with ruxolitinib. In: Ann Hematol 2015; 94(11): 1929-1930 [IF 2,634]
  • Wang SY, Ebert T, Jaekel N, Schubert S, Niederwieser D, Al-Ali HK: Miliary tuberculosis after initiation of ibrutinib in chronic lymphocytic leukemia. In: Ann Hematol 2015; 94(8): 1419-1420 [IF 2,634]

letzte Änderung: 26.07.2012

Kontakt

Abteilung für Hämatologie und Internistische Onkologie
Niederwieser, Dietger (Prof. Dr.)
Liebigstraße 20 a
04103 Leipzig
Telefon: +49 341 97-13050
Fax: +49 341 97-13059
E-Mail

Kontakt

Dezernat für Forschungs- und Transferservice
Ritterstraße 26
(3. Etage)
04109 Leipzig
Telefon: +49 341 97-35000
Telefax: +49 341 97-35009
E-Mail

Filtern

Wählen Sie bitte das Berichtsjahr.



Suche